N Jayakumar, Group CEO and MD of Prime Securities, sees export manufacturing benefiting from a weaker rupee and high interest rates. He remains positive on Indian generics, citing global drug shortages and low investor ownership. Could pharma and manufacturing lead the next growth cycle? Disclaimer: The views and tips expressed by investment experts on CNBCTV18.com are their own, not of the website or its management. CNBCTV18.com advises users to check with certified experts before taking any investment decisions.
Source link
Weak rupee, high rates make export manufacturing attractive; pharma sees long tailwind: N Jayakumar
